News on lab-developed tests and emerging diagnostic technologies.
Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.
Quest's QHerit will screen for 22 disorders and is based on recommendations issued this year by the American College of Obstetricians and Gynecologists.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The tubes enable noninvasive collection and preservation of biomarkers, such as circulating or total nucleic acids, and protein and cellular biomarkers.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
